Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain (Predictio)

• Status: Completed
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Drug therapy in patients with chronic low back pain is a major challenge for physicians. One of the problems is the lacking knowledge in prediction of drug efficacy in a chosen patient. Usually one of the classes of pain medication is given to patients with a similar clinical picture, although different pain mechanisms may be responsible for this clinical picture.

Another reason for variable drug efficacy are genetic polymorphisms, this may be the reason why an unique drug produces different responses (from a lacking analgesic effect up to excessive effect or side-effects.

Quantitative sensory testing is a method that documents alterations in the pain perception system. Linking genetic polymorphisms to quantitative sensory testing may give us a tool for anticipation of drug efficacy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital Inselspital, Berne
• Collaborators: Aalborg University; University of Bern; University of Zurich
• Treatments: Clobazam; Imipramine; Oxycodone; Tolterodine Tartrate

Criteria

Inclusion Criteria:

• Low back pain with NRS>2

• Chronic low back pain since more than 6 months

Exclusion Criteria

• pregnancy

• use of pain medication other than paracetamol and ibuprofen in the last 7 days

• suspicion of radicular pain

• suspicion of intervertebral disk herniation

• foraminal intervertebral stenosis

• suspicion of polyneuropathy

• diabetes

• parkinson disease

• alzheimer disease

• glaucoma

• prostata hyperplasia or voiding problems

• known heart rhythm problems

• heart insufficiency NYHA 3-4

• Systemic inflammatory disease

• Ongoing oncologic disease

• drug or alcohol abuse

• Significant depressive disease (BDI-FS>9)